Silence Therapeutics plc’s (LON:SLN) bid to protect a “fundamental” chemical modification it says is integral to the emerging science of RNA interference (RNAi) took a fresh turn.
One of the companies in its cross-hairs, the US giant Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), has responded robustly to legal action initiated by Silence.
READ: Silence Therapeutics granted yet more US patents for its innovative chemical modification
Silence has over the past year sought to shore up the patent protection around what it calls a “foundational innovation” that is core to the emerging RNAi industry.
It also believes a number of companies have been using its technology in drugs that silence genes and may be fundamental in the war against cancer.
Among those cited as using Silence’s advance was the aforementioned American biotech Alnylam, valued at US$12.5bn.
Silence has previously made claim for declaratory relief relating to its entitlement to Supplementary Protection Certificates on certain Alnylam products.
Declaratory relief is a court judgement that determines the rights of a person or a company without ordering anything to be done or awarding damages.
Supplementary Protection Certificates, as the name suggests, extend the protection of certain active ingredients in drugs.
READ: The full Silence release
As part of its action Silence named as defendants Alnylam UK Limited, Alnylam Pharmaceuticals Inc, and The Medicines Company UK Limited.
"Normal course of business at the commencement of litigation"
It emerged Friday that Alnylam UK Limited and The Medicines Company UK Limited have hit back by suing to revoke Silence’s European patent in the UK.
This also includes claims for declarations of non-infringement of this European patent by certain Alnylam products.
Silence said it regards the Alnylam counter-actions as simply the "normal course of business at the commencement of litigation”.
It added that it continues to believe that “certain Alnylam products require a licence under the Silence patent estate”.
Chief executive Ali Mortazavi told investors: "During 2017, both the European and US patent offices have continued to uphold the validity of our expanding patent estate with the granting of additional patents.
“We believe that our fundamental chemical modification technology is core foundational innovation for today's RNAi sector, and that therefore those companies using such modification technology within the scope of our intellectual property will require a licence.
“Silence is committed to defending its position and to securing the appropriate recognition and associated value for its IP."